US EditionStudy identifies setmelanotide as a potential treatment for Obesity Hypoventilation Syndrome
Summary by bariatricnews.net
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Study identifies setmelanotide as a potential treatment for Obesity Hypoventilation Syndrome
Researchers from the George Washington University have uncovered evidence in an animal study that shows setmelanotide, an FDA-approved medication for a rare genetic obesity disorder, may offer a pathway for treating a life-threatening form of sleep-disordered breathing called Obesity Hypoventilation Syndrome.Obesity Hypoventilation Syndrome which affects an estimated five to 10 million Americans commonly coexists with obstructive sleep apnoea. W…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
